Glenmark has recently launched Remogliflozin - a novel SGLT2 inhibitor- and India is the first country to get access to this innovative drug. Remogliflozin has been s tudied in 26 clinical trials globally, covering about 2,500 patients from various ethnicities . Phase III clinical trials are the best way to find a new paradigm for treatment and change the way how doctors treat patients. Glenmark invites you for an interactive webinar on 22nd May 2019 from 9 pm onwards . In this webinar, Dr.
Manoj Chawla and Dr. Sadanand Shetty will talk about the "Indian Experience Of Remogliflozin- Phase III Clinical Study". We invite you to submit your questions which will be answered by the speakers at the end of the session.
